1. Home
  2. ARVN
  3. ARVN News

Latest Arvinas Inc. (ARVN) News on April 2, 2025

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
ARVN

GlobeNewswire

6 days ago

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
ARVN

Zacks

14 days ago

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?
ARVN

Insider Monkey

14 days ago

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
ARVN

Zacks

16 days ago

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
ARVN

Zacks

16 days ago

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Biotech Alert: Searches spiking for these stocks today
ARVN

TipRanks

19 days ago

Biotech Alert: Searches spiking for these stocks today

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
ARVN

Zacks

19 days ago

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
ARVN

Zacks

20 days ago

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
ARVN

Zacks

20 days ago

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

ARVN

MT Newswires

20 days ago

Goldman Sachs Downgrades Arvinas to Neutral From Buy, Cuts Price Target to $15 From $70

ARVN

MT Newswires

21 days ago

Arvinas' Vepdegestrant Likely to Have 'Restricted Label' in Breast Cancer, Wedbush Says

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
ARVN

Zacks

21 days ago

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study

ARVN

MT Newswires

21 days ago

Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
ARVN

Investor's Business Daily

22 days ago

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

ARVN

MT Newswires

22 days ago

Citigroup Cuts Arvinas' Price Target to $10 From $19, Maintains Neutral Rating

ARVN

MT Newswires

22 days ago

Top Midday Decliners

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
ARVN

Clinical Trials Arena

22 days ago

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients

ARVN

MT Newswires

22 days ago

Oppenheimer Downgrades Arvinas to Perform From Outperform

ARVN

MT Newswires

22 days ago

Sector Update: Health Care

ARVN

MT Newswires

22 days ago

Arvinas, Pfizer Say Vepdegestrant Trial Meets Primary Endpoint in Breast Cancer With ESR1 Mutations

ARVN

MT Newswires

22 days ago

Top Premarket Decliners

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
ARVN

GlobeNewswire

22 days ago

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas to Participate in Upcoming Investor Conferences
ARVN

GlobeNewswire

a month ago

Arvinas to Participate in Upcoming Investor Conferences

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know
ARVN

Zacks

a month ago

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

ARVN

MT Newswires

a month ago

Arvinas Insider Sold Shares Worth $523,881, According to a Recent SEC Filing

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago
ARVN

Simply Wall St.

a month ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy
ARVN

Zacks

2 months ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%
ARVN

Zacks

2 months ago

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

ARVN

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating

ARVN

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Arvinas Inc Earnings Call

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...
ARVN

GuruFocus.com

2 months ago

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
ARVN

Zacks

2 months ago

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

ARVN

MT Newswires

2 months ago

Arvinas' Q4 Loss Narrows, Revenue Misses Analysts' Expectations

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ARVN

GlobeNewswire

2 months ago

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings
ARVN

GuruFocus.com

2 months ago

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
ARVN

GlobeNewswire

2 months ago

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
ARVN

Motley Fool

2 months ago

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

ARVN

MT Newswires

3 months ago

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
ARVN

GlobeNewswire

3 months ago

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial
ARVN

Clinical Trials Arena

4 months ago

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
ARVN

Benzinga

4 months ago

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

ARVN

MT Newswires

4 months ago

Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
ARVN

GlobeNewswire

4 months ago

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
ARVN

Insider Monkey

4 months ago

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
ARVN

GlobeNewswire

4 months ago

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
ARVN

GlobeNewswire

4 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode
ARVN

Insider Monkey

4 months ago

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Arvinas to Participate in Upcoming Investor Conferences
ARVN

GlobeNewswire

5 months ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Third Quarter 2024 Earnings: Beats Expectations
ARVN

Simply Wall St.

5 months ago

Arvinas Third Quarter 2024 Earnings: Beats Expectations

ARVN

MT Newswires

5 months ago

UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...
ARVN

GuruFocus.com

5 months ago

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

ARVN

MT Newswires

5 months ago

Arvinas' Q3 Net Loss Narrows, Revenue Rises

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
ARVN

Zacks

5 months ago

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ARVN

GlobeNewswire

5 months ago

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings
ARVN

GuruFocus.com

5 months ago

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely
ARVN

Simply Wall St.

5 months ago

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential
ARVN

Insider Monkey

5 months ago

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
ARVN

GlobeNewswire

5 months ago

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
ARVN

GlobeNewswire

5 months ago

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago
ARVN

Simply Wall St.

7 months ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares
ARVN

GuruFocus.com

7 months ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now
ARVN

Insider Monkey

7 months ago

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Arvinas to Participate in Upcoming Investor Conferences
ARVN

GlobeNewswire

7 months ago

Arvinas to Participate in Upcoming Investor Conferences

Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts
ARVN

Simply Wall St.

8 months ago

Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
ARVN

Simply Wall St.

8 months ago

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

ARVN

MT Newswires

8 months ago

Oppenheimer Adjusts Arvinas Price Target to $50 From $70, Maintains Outperform Rating

ARVN

MT Newswires

8 months ago

Arvinas' Q2 Net Loss Narrows as Revenue Rises; Names Andrew Saik CFO

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
ARVN

Zacks

8 months ago

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
ARVN

GlobeNewswire

8 months ago

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
ARVN

GlobeNewswire

8 months ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Biotech Arvinas Stock Earns 82 RS Rating
ARVN

Investor's Business Daily

9 months ago

Biotech Arvinas Stock Earns 82 RS Rating

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
ARVN

Zacks

9 months ago

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

Milestone Pharmaceuticals Refreshes Board of Directors
ARVN

GlobeNewswire

9 months ago

Milestone Pharmaceuticals Refreshes Board of Directors

Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?
ARVN

Insider Monkey

9 months ago

Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?

ARVN

MT Newswires

9 months ago

Arvinas Names Andrew Saik as Chief Financial Officer; Shares Rise After Hours

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
ARVN

GlobeNewswire

9 months ago

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
ARVN

Zacks

9 months ago

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
ARVN

GlobeNewswire

9 months ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
ARVN

GlobeNewswire

10 months ago

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
ARVN

CNW Group

10 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
ARVN

CNW Group

10 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
ARVN

PR Newswire

10 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
ARVN

Business Wire

10 months ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts
ARVN

AFP

10 months ago

New Zealand scraps plan to tax livestock burps, farts

ARVN

Business Wire

10 months ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
ARVN

The Wall Street Journal

10 months ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool
ARVN

Bloomberg

10 months ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Arvinas to Participate in Upcoming Investor Conferences
ARVN

GlobeNewswire

10 months ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
ARVN

GlobeNewswire

10 months ago

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope
ARVN

Simply Wall St.

10 months ago

It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope

ARVN

MT Newswires

a year ago

Sector Update: Health Care Stocks Steady Premarket Thursday

ARVN

MT Newswires

a year ago

Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity

ARVN

MT Newswires

a year ago

Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
ARVN

GlobeNewswire

a year ago

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
ARVN

Simply Wall St.

a year ago

Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
ARVN

GlobeNewswire

a year ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

ARVN

MT Newswires

a year ago

Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
ARVN

Simply Wall St.

a year ago

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

ARVN

MT Newswires

a year ago

Arvinas Shares Up After Q1 Net Loss Narrows

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
ARVN

Zacks

a year ago

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

Share on Social Networks: